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BACKGROUND: Antiretroviral therapy containing an integrase 
strand transfer inhibitor plus two Nucleoside Reverse 
Transcriptase inhibitors has now been recommended for 
treatment of HIV-1-infected patients. This thus determined 
possible pre-existing integrase resistance-associated mutations in 
the integrase gene prior to introduction of integrase inhibitors 
combination therapy in Kenya.   
METHODS: Drug experienced HIV patients were enrolled at Kisii 
Teaching and Referral in Kenya. Blood specimens from (33) 
patients were collected for direct sequencing of HIV-1 pol-
integrase genes. Drug resistance mutations were interpreted 
according to the Stanford algorithm and phylogenetically analysed 
using insilico tools.  
RESULTS: From pooled 188 Kenyan HIV integrase sequences that 
were analysed for drug resistance, no major mutations conferring 
resistance to integrase inhibitors were detected. However, 
polymorphic accessory mutations associated with reduced 
susceptibility of integrase inhibitors were observed in low 
frequency; M50I (12.2%), T97A (3.7%), S153YG, E92G (1.6%), 
G140S/A/C (1.1%) and E157Q (0.5%). Phylogenetic analysis (330 
sequences revealed that HIV-1 subtype A1 accounted for majority 
of the infections, 26 (78.8%), followed by D, 5 (15.2%) and C, 2 
(6%). 
CONCLUSION: The integrase inhibitors will be effective in Kenya 
where HIV-1 subtype A1 is still the most predominant. However, 
occurring polymorphisms may warrant further investigation 
among drug experienced individuals on dolutegravir combination 
or integrase inhibitor treatment 
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By 2017, it was estimated that about 20.9 million 
people living with HIV were on Antiretroviral 
Therapy (ART) worldwide (1), with estimated 
25 million expected to receive ART by 2020 (2). 
However, according to the Kenyan national HIV 
estimates, 1,517701 people were living with HIV, 
of whom 897,644 were on treatment with 
antiretroviral therapy with 620,057 still in need 
(3).Since the introduction, free ART in Kenya, 
HIV-1 associated morbidity and mortality have 
significantly reduced (4). These drugs suppress 
viral replication hence reduce viral loads thus 
helping in maintaining the immune system.  
However, these benefits could be limited with 
development of drug resistance leading to 
treatment failure. Previous studies conducted in 
Kenya have continuously to show an increasing 
trend in HIV drug resistance to NNRTI,  NRTI 
and PIs (5-7) hence the need to revise and 
introduce new classes of drugs in the treatment 
program. The integrase inhibitors (raltegravir, 
dolutegravir and elvitegravir) are the latest 
antiretroviral (ARV) drugs that have been 
developed and approved for treatment of HIV-1 
infections (8).  INSTI-based regimens are now the 
recommended and preferred first-line ART for the 
treatment of HIV-1 infection in ART-naïve patients 
due to their favorable side effect profile, limited 
drug-drug interactions, and its effectiveness in viral 
suppression (6). The Kenya National AIDS Control 
Council Programme (NASCOP) revised its 
treatment guidelines and adopted dolutegravir, an 
InSTI drug, as first-line drug. For better patient’s 
response to treatment with viral suppression, this 
approach was used as a way towards 
implementation of ambitious 90-90-90 UNAIDS 
strategic to end the AIDS epidemic by 2020. The 
Ministry of Health has already started to implement 
these guidelines with Nairobi County as a pilot as 
they roll out the program to the rest of the country. 
Kenya is therefore among the first African 
countries to initiate this program in both drug naïve 
and experienced patients (9). Previous studies have 
confirmed that dolutegravir is very effective among 
drug naïve patients. Due to its low genetic barrier, 
it is easily resisted with development of drug 
resistance associated mutations (7). This study 
was, therefore, appropriate in evaluating any 
possible preexisting HIV drug resistance against 
INSTI in order to guide its implementation across 
the country.  
 
METHODS AND PATIENTS 
 
A cross-sectional pilot study was conducted and 
stratified approach used in recruiting HIV infected 
individuals originating from different geographical 
parts of the Kisii County but enrolled at HIV 
comprehensive clinic at Kisii level five teaching 
referral hospital. Approximately, 5ml venous blood 
was drawn from consenting participants and used 
for the analysis. Demographical data on age, 
gender and ARVs status was obtained through 
administered structural questionnaire. The study 
was approved by the Ethical Committee of 
Kenyatta University. The study was conducted 
according to the criteria set by the declaration of 
Helsinki and each subject signed informed consent 
before participating in the study.  
Viral DNA Extraction and amplification: Viral 
DNA was extracted from collected blood using 
QIAamp MinElute Virus kit (Qiagen Inc., 
Valencia, CA) according to the manufacturers' 
instructions. A part of the partial HIV-1 pol gene 
covering 288bp of the integrase (corresponding to 
4493–4780 nt in HIV-1 HXB2) was amplified by 
nested polymerase chain reaction (PCR) using 








the second round respectively. Amplification 
conditions were 1 cycle of 95°C, 10 min, 35 cycles 
of 95°C, 30s, 45°C, 30s, 72°C, 60s and final 
extension for 72°C for 7min (6). Amplified 
products were confirmed by ethidium bromide 
stained gel electrophoresed and visualised under 
ultraviolet light and directly sequenced (Applied 
Biosystems, Foster City, CA) using the 
manufacturer’s protocol as previously described (5-
6). The generated sequences were analysed for the 
presence of resistance associated 
substitution/mutations using Stanford HIV drug 
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resistance database (http://hivdb.stanford.edu/) and 
mutations compared to those of IAS drug 
resistance algorithm. 
CD4+ T cell counts: Baseline CD4+ T cell count 
was performed using a FACSCalibur flow 
cytometer (Becton-Dickinson, NJ) equipped with 
automated acquisition and analysis software 
according to the manufactures instructions. The 
ART status of the study subjects were determined 
prior to recruitment and baseline CD4+counts 
determined.  
Phylogenetic analysis: The generated sequences 
were phylogenetically analysed using MEGAx 
software. Generated sequences were aligned and 
joined together with reference sequences using 
Clustal W (version 1.6.6) and Neighbour-joining 
softwares respectively. Phylogenetic tree was then 
inferred by Tree View software (version 1.6.6) at 
bootstrap resampling (1000 data sets) for statistical 
robustness (12).  
Genotypic drug resistance analysis: The 
generated sequences from this study (33) were 
pooled together with all other Kenyan integrase 
sequences from the Gen Bank (155) and analysed 
for possible drug resistance associated mutations. 
Genotypic drug resistance in the HIV-1 pol-
integrase region was defined as the presence of one 
or more resistance-related mutations, as specified 
by the consensus mutation figures of the 
International AIDS Society-USA (6,14).  
Ethical approval and consent participate: This 
study was approved by the Ethical Committee of 
Kenyatta University and permission by Hospital 
ethical management committee. The study was 
conducted according to the criteria set by the 
declaration of Helsinki and each subject signed an 




Study populations: A pilot study was conducted 
targeting HIV infected patients attending HIV 
comprehensive clinics of Kisii Teaching and 
Referral Hospital. A total of 33 consenting drug 
experienced individuals consisting females (20) 
and males (13) were recruited into the study during 
the period between January and July 2018. The 
average age of the studied subjects was 47.8 years 
for males and 27 years for females. The ages 
ranged from14 to 73 years.  From the CD4 counts 
findings, the majority of the participants had their 
CD4 counts above 500 Cells/mm3 (Table 1). The 
CD4 lymphocyte count ranged from 220 to 998 
Cells/mm3 with average of 522 Cells/mm3. We 
compared if gender and age had any relationship 
with the CD4 counts. From the analysis, neither 
gender (p=0.576) nor age (p=0.844) had significant 
difference in relation to levels of CD4 counts. 
   
 
Table 1. Characteristics of Kenyan HV infected patients in Kisii prior to introduction of integrase inhibitors. 
 
    Drug experienced patients 
Gendera 
  ALL FEMALE MALE 
  N=33 (n=20) (n = 13 ) 
Age (years) ranges  (15-73)  (15-54)  (26-73) 
Mean  33.8 27 48 
CD4+  T cell count (Cells/mm3) 
  
  
Mean (Range) 522(200-998) 536.8 SE40.1 (200-896) 575.8 SE59.7(220-998) 
<300 3 2 1 
301-400 5 3 2 
400-500 9 4 5 
>500 16 11 5 
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Integrase drug resistance: Thirty three (33) 
sequences from this study were pooled together 
with 155 Kenyan integrase sequences from the Los 
Alamos database accessed on May 12th, 2019 
(Supplementary data) and analysed for drug 
resistance mutations.  Drug resistance was defined 
according to the Stanford HIVdb’s 
(http://hivdb.stanford.edu/) as guided by 
International AIDS Society-USA. All 188 
sequences were analysed for HV-1 drug resistance. 
From analysis of these integrase sequences, no 
primary mutations (Y143R=C=H, Q148H=R=K, 
and N155H=S) associated with reduced 
susceptibility to the integrase inhibitors Raltegravir 
and Elvitegravir were detected.  However, about 
20% of the analysed sequences had mutations 
associated with reduced susceptibility to INSTI. 
These mutations were M50I (12.2%), T97A 
(3.7%), S153YG, E92G (1.6%), G140S/A/C 
(1.1%) and E157Q (0.5%). In addition, these 
sequences had also naturally occurring 
polymorphisms. HIV subtypes were analysed for 
any possible relationship with occurrence of HIV-1 
drug mutations. From the analysis, there is no 
relationship between HIV subtype and occurrence 
of drug resistance (Table 2). 
HIV-1: subtype distribution: Phylogenetic 
analyses of the (33) sequences revealed that the 
majority of the sequences belonged to A1: 26 
(78.8%) followed by D: 5 (15.2%) and then C: 
2(6%) (Figure 1). 
  




Integrase Mutations Frequency 188(n) % 
none 165 87.8 
M50I 23 12.2 
E157Q 1 0.5 
L74M/I 3 1.6 
T97A 7 3.7 
G140S/A/C 2 1.1 
S153YG 1 1.6 
E92G 1 1.6 
E92V 1 1.6 
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Figure 1: Phylogenetic tree of the HIV -1 pol -integrase sequences from Kisii region in relation to reference 
sequences from the Los Alamos HIV database 
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In the present study, HIV-1 strains sampled in Kisii 
were characterised based on pol-integrase region. 
Like in the rest of parts of the country, the majority 
of the analysed sequences belonged to HIV-1 
subtype A1 with HIV-1 subtype C being the least. 
These findings agree with previous studies on the 
predominance of HIV1 subtype A1 in Kenya 
(6,10,16). Sequences belonging to HIV-1 subtype 
A1 clustered with sequences from Kenya, Uganda 
and Sweden. The fact that these sequences 
clustered with those from the neighborhood 
countries, there is a likelihood of them having a 
common evolutionary origin (16). The sequences 
aligned mainly with those from Kenya, indicating 
possible Kenyan origin. The sequences that were 
HIV subtype C clustered with reference sequences 
from Kenya, Zambia, Canada and Botswana. The 
HIV-1 subtype D sequences clustered with 
reference sequences from Kenya (5-6,16). From 
these findings, the commonly detected subtypes 
A1, C and D were detected though with no 
recombinants. This does not rule out possible 
circulation of recombinants based possible intra-
transmission of these viral strains within Kenya 
borders. Nevertheless, based on amplified small 
gene fragment, this may not have allowed detection 
of possible viral recombinants. These findings 
confirm that the HIV transmission occurs within 
Kenyan borders. There is compelling evidence that 
variation in HIV-1 subtypes could influence the 
development of drug resistance and the 
susceptibility to certain antiretroviral drugs (17-
18). Certain integrase mutations do differ 
according to subtype in response to integrase 
inhibitor efficacy (19). From our analysis, 
however, there was no significant relationship of 
HIV-1 subtypes and occurrence of mutations. 
Three INSTIs, drugs, RAL, DTG and EVG are 
new class of drugs that have been approved for 
clinical use by the FDA and European Medicines 
Agency (8). These drugs have shown to be highly 
efficient for the treatment of both ARV-naïve and -
experienced individuals even with preexisting drug 
resistance or treatment complication (20). Based on 
these findings, several countries including Kenya 
have revised their treatment guideline and adopted 
INSTIs in their treatment guidelines. Kenya for 
instance, by the year 2018, started rolling out this 
guideline with its implementation being piloted in 
Nairobi before rolling it out to the rest of the 
country.  
In Kenya, provision of free antiretroviral 
(ARVS) to the public began in 2003. This has 
significantly promoted its access to AIDS patients 
(7). With current WHO guideline “diagnose and 
treat”, the demand for ARVs has significantly 
increased. In this study, we analysed for any 
possible preexisting drug resistance mutations prior 
to INSTIs introduction. From our analysis, no 
major or minor mutations associated with reduced 
susceptibility to INSTIs dolutegravir, Raltegravir 
and Elvitegravir or Bictegravir were detected 
(Table 2). According to previous studies and the 
fact that INSTIs have not yet been introduced in 
Kenya, polymorphic accessory mutations that are 
associated with reduced susceptibility to 
Raltegravir and Eletegravir were detected. These 
mutations (Table 2) occurred in low frequencies 
which suggests that the INSTIs could be effective. 
Based on high genetic barrier to resistance in 
dolutegravir, detected mutations were only those 
associated with raltegravir and eletegravir that have 
a low genetic barrier. These mutations being 
polymorphic in drug sensitive HIV-1, these 
mutations could naturally enhance viral fitness and 
virulence (20).  This study confirms previous 
findings that detected these naturally occurring 
polymorphisms, suggesting possible adaptation to 
immune or drug pressures (6). These mutations 
could occur even at positions that could be linked 
to drug resistance to either dolutegravir raltegravir 
or eletegravir (6). Polymorphic mutations were 
detected among the analysed sequences (Table 2). 
These mutations are known to be associated with 
potential high level of resistance to RAL and EVT, 
which in combination with major mutation could 
synergistically reduce susceptibility INSTIs. Even 
though dolutegravir could be preferred regimen, its 
efficacy could be limited with development drug 
resistance as INSTIs are being rolled out for the 
management of HIV/AIDS. Based on this 
development, continued surveillance of INSTI 
resistance in the country is invertible.  
Despite being a pilot study, no major mutations 
associated with INSTIs drug resistance were 
detected. However, naturally occurring 
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polymorphisms were detected at low frequency. 
Such mutations have not been associated with any 
drug resistance. These findings, therefore, confirm 
that treated HIV-1 infected Kenyans are likely to 
benefit from INSTI-based drug regimens, 
especially at this time when there is increasing 
trends of HIV drug resistance against reverse 
transcriptase inhibitors, which are currently being 
used in the country. Like the rest parts of the 
Country, HIV-1 subtype A1 remains the most 




1. UNAIDS. Fact Sheet–Latest Statistics on the 
Status of the AIDS Epidemic. 2017. 
(Available from: 
http://www.unaids.org/en/resources/fact-
sheet) (Accessed 07 December 2018). 
2. Estill, J., Ford N., Salazar-Vizcaya, L., Haas, 
A. D., Blaser, N., Habiyambere, V et al. The 
need for second-line antiretroviral therapy in 
adults in sub-Saharan Africa up to 2030: a 
mathematical modelling study. The Lancet 
HIV, 2016;3(3): e132-e139. 
3. National AIDS and STI Control Program 
(NASCOP) Kenya Ministry of Health. 
(2018). Guidelines on Use of Antiretroviral 
Drugs for Treating and Preventing HIV in 
Kenya. 
4. Mukui, I. N., Williamson, J., Wamicwe, J. N., 
Vakil, S., Katana, A., & Kim, A. A. Rates and 
predictors of non-adherence to antiretroviral 
therapy among HIV-positive individuals in 
Kenya: results from the second Kenya AIDS 
indicator survey, 2012. PloS 
one, 2016;11(12):e0167465. 
5. Lihana, R.W., Khamadi, S.A., Lubano, K., 
Lwembe, R., Kiptoo, M.K., Lagat, N., et al. 
HIV type 1 subtype diversity and drug 
resistance among HIV type 1-infected 
Kenyan patients initiating antiretroviral 
therapy. AIDS research and human 
retroviruses, 2009;25(12):1211-1217. 
6. Nyamache, A. K., Muigai, A. W., Nganga, Z., 
& Khamadi, S. A. HIV Type 1 genetic 
diversity and naturally occurring 
polymorphisms in HIV type 1 Kenyan 
isolates: implications for integrase 
inhibitors. AIDS research and human 
retroviruses, 2012;28(8):933-936.  
7. Koigi, P., Ngayo, M. O., Khamadi, S., Ngugi, 
C., & Nyamache, A. K. HIV type 1 drug 
resistance patterns among patients failing first 
and second line antiretroviral therapy in 
Nairobi, Kenya. BMC research 
notes, 2014;7(1):890. 
8. Alaoui, N., El Alaoui, M. A., Touil, N., El 
Annaz, H., Melloul, M., Tagajdid, R., et al. 
Prevalence of resistance to integrase strand-
transfer inhibitors (INSTIs) among untreated 
HIV-1 infected patients in Morocco. BMC 
research notes, 2018;11(1): 369. 
9. Mesplede, T., & Wainberg, M. A. Integrase 
strand transfer inhibitors in HIV 
therapy. Infectious diseases and 
therapy, 2013;2(2):83-93. 
10. Lihana, R.W., Khamadi, S.A., Lubano, K., 
Lwembe, R., Kiptoo, M.K., Lagat, N., et al. 
HIV type 1 subtype diversity and drug 
resistance among HIV type 1-infected 
Kenyan patients initiating antiretroviral 
therapy. AIDS research and human 
retroviruses, 2009;25(12): 1211-1217. 
11. Brado, D., Obasa, A. E., Ikomey, G. M., 
Cloete, R., Singh, K., Engelbrecht, S., et al. 
Analyses of HIV-1 integrase sequences prior 
to South African national HIV-treatment 
program and available of integrase inhibitors 
in Cape Town, South Africa. Scientific 
reports, 2018;8(1):4709 
12. Kimura M. A simple method for estimating 
evolutionary rates of base substitution 
through comparative studies of nucleotide 
sequences. J Mol Evol, 1980; 16:111–120. 
13. Saitou N and Nei M.The neighbour-joining 
method: a new method for reconstructing 
phylo-genetic trees. Molecular Biology and 
Evolution, 1987;4: 406-425.  
14. Johnson, V. A., Brun-Vézinet, F., Clotet, B., 
Gunthard, H. F., Kuritzkes, D. R., Pillay, D & 
Richman, D. D. Update of the drug resistance 
mutations in HIV-1: 2009. Top HIV 
Med, 2009;17(5):138-145 
15. Msimanga, P. W., Vardas, E., & Engelbrecht, 
S. HIV-1 diversity in an antiretroviral 
                 Ethiop J Health Sci.                           Vol. 30, No. 1                                     January 2020 
 
 




treatment naïve cohort from Bushbuckridge, 
Mpumalanga Province, South 
Africa. Virology journal, 2015;12(1). 
16.  Khamadi, S.A., Ochieng, W., Lihana, R.W., 
Kinyua, J., Muriuki, J., Mwangi, J., et al. HIV 
type 1 subtypes in circulation in northern 
Kenya. AIDS Research & Human 
Retroviruses, 2005;21(9):810-814. 
17. Lessells, R. J., Katzenstein, D. K., & De 
Oliveira, T. Are subtype differences 
important in HIV drug resistance? Current 
opinion in virology, 2012;2(5):636-643. 
18. Bar-Magen T, Donahue DA, McDonough EI, 
Kuhl BD, Faltenbacher VH, Xu H, Michaud 
V, et al. HIV-1 subtype B and C integrase 
enzymes exhibit differential patterns of 
resistance to integrase inhibitors in 
biochemical assays. AIDS. 2010;24(14): 
2171-2179. 
19. Xiao, H., Xue, Y., Gu, S., Wang, J., Sun, H., 
& Lu, H. Efficacy and safety of antiretroviral 
regimens including raltegravir to treat HIV-
infected patients with hemophilia. Bioscience 
trends, 2016;10(1):42-46.  
20. Meixenberger K, Yousef KP, Smith MR, 
Somogyi S, Fiedler S, Bartmeyer B, 
Hamouda O, et al. Molecular evolution of 
HIV-1 integrase during the 20 years prior to 
the first approval of integrase inhibitors. Virol 
J.; 2017;14:(1)23.  
21. Arruda, L. B., Fonseca, L. A. M., Duarte, A. 
J., & Casseb, J. Genetic diversity on the 
integrase region of the pol gene among HIV 
type 1-infected patients naive for integrase 
inhibitors in Sao Paulo City, Brazil. AIDS 
research and human 
retroviruses, 2010;26(1):105-107. 
 
 
 
 
